Psychedelic Palliative Care

Bottom line: Psychedelic-assisted interventions may be associated with reduced depression, anxiety, and existential distress in palliative care patients, but evidence remains limited and inconsistent due to varying study quality and accessibility challenges.

Right now, somewhere in a hospital, a patient with a life-limiting illness is dealing with something beyond physical pain — they’re struggling with existential distress, demoralization, and a loss of meaning. That kind of suffering doesn’t always respond well to standard treatments. Could a different kind of therapy help? Psychedelic-assisted interventions — including ketamine-assisted psychotherapy — are being studied for their potential to ease this kind of suffering. But does the evidence support their use in palliative care?

The Emerging Evidence

A recent review of the literature on psychedelic-assisted therapies in palliative care and serious illness found some encouraging results. Across 22 studies, these therapies were consistently linked to reductions in depression, anxiety, and existential distress. Patients also reported improved quality of life and spiritual well-being. Safety was generally good in controlled settings. But the quality of the interventions varied — preparation, setting, clinician training, and how therapy was integrated into care were inconsistent across studies. That inconsistency raises questions about how reliable these results are.

A Closer Look at the Studies

One systematic review and meta-analysis looked at psilocybin and ketamine for psychosocial symptoms in adults with cancer. The analysis of four ketamine RCTs found large, rapid effects on depression and anxiety — a Hedges’ g of -1.37. Three psilocybin RCTs showed a large effect on depression, with a Hedges’ g of -3.13. Another study reviewed psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression, finding rapid, robust, and sustained antidepressant effects. But there are still significant challenges — high costs, limited accessibility, and regulatory barriers.

The Mechanisms Behind the Effects

So, how do these therapies work? Psilocybin mainly acts on serotonin 5-HT2A receptors, changing brain networks and boosting neuroplasticity. That can lead to faster and more lasting improvements in mood and thinking. Ketamine, meanwhile, blocks NMDA receptors and increases glutamate release — a mechanism that can lead to rapid antidepressant effects, often within hours. Understanding these mechanisms is important for creating better treatment protocols and improving outcomes.

Frequently Asked Questions

1. What are psychedelic-assisted interventions, and how do they work?
   Psychedelic-assisted interventions use substances like psilocybin or ketamine along with psychotherapy to treat mental health conditions.

2. Are these therapies safe, and what are the potential risks?
   Safety is generally good under controlled conditions, but risks include adverse reactions, increased anxiety, and psychosis.

3. Can these therapies be used to treat any mental health condition?
   Currently, the evidence supports their use for depression, anxiety, and existential distress in patients with life-limiting illnesses.

4. Are these therapies widely available, and what are the barriers to access?
   They’re not widely available — regulatory hurdles, high costs, and limited access are major barriers.

5. What is the current state of research in this field, and what are the future directions?
   The research is promising but still early. More studies are needed to fully understand these therapies and to develop standardized protocols for clinical use.

Sources

• ¶Psychedelic-Assisted Interventions in Palliative Care: A Narrative Overview and Critical Evaluation
• ¶Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis
• ¶PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.